Prostate Health Market Set for Strong Growth to USD 99.41 Billion by 2033, Led by North America's 45% Market Share | Key Players - Novartis AG, Bayer AG, Pfizer Inc.

The global Prostate Health Market reached US$ 41.34 billion in 2024 and is expected to reach US$ 99.41 billion by 2033, growing at a CAGR of 9.1% during the forecast period 2025-2033.The market's strong growth is driven by rising prostate cancer prevalence, expanded screening and diagnostics, and major industry partnerships and approvals-such as the exclusive licensing deal for the PSMA imaging agent PYLARIFY® in Japan and new AI-powered diagnostic collaborations enhancing early detection and personalized care.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/prostate-health-market?prtk

Key Industry Developments

United States: Key Industry Developments

✅ December 2025: FDA granted regular approval to rucaparib (Rubraca) for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) post androgen receptor therapy, based on phase 3 TRITON3 trial showing improved radiographic progression-free survival.

✅ June 2025: Telix Pharmaceuticals launched Gozellix, a next-generation PSMA-PET imaging agent for prostate cancer diagnosis, now commercially available in the US market.

✅ March 2025: FDA approved expanded indication for Novartis' Pluvicto (radioligand therapy) for earlier use in PSMA-positive mCRPC before chemotherapy, demonstrating delayed disease progression.

Japan: Key Industry Developments

✅ October 2025: Curium Group, PeptiDream, and PDRadiopharma enrolled the first patient in a registrational Phase 2 clinical trial for 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting PSMA in prostate cancer cells.

✅ March 2025: Japanese Ministry of Health, Labor and Welfare approved LYNPARZA (olaparib) plus abiraterone and prednisolone for BRCA-mutated metastatic castration-resistant prostate cancer, showing improved rPFS and OS from PROpel trial data.

✅ January 2025: Teleflex released the UroLift 2 System for enlarged prostate (BPH) procedures, emphasizing office-based, catheter-free treatment options in the US market with potential expansions noted regionally.

Key M&A Deals
✅ Johnson & Johnson agreed to acquire Halda Therapeutics Inc. for USD 3.05 billion in November 2025, bringing a promising prostate cancer therapy pipeline into its oncology portfolio and reinforcing its leadership in targeted cancer treatment development.

✅ BioMarin Pharmaceutical Inc. announced the USD 4.8 billion acquisition of Amicus Therapeutics in December 2025, strengthening its rare disease drug offerings with approved therapies for Fabry and Pompe diseases and expanding its biologics and specialty treatment portfolio.

✅ Genmab completed the USD 8 billion acquisition of Merus on 31 December 2025, gaining full control over a late-stage oncology antibody pipeline and enhancing its position in cancer therapeutics research and commercialization.

✅ Stryker Corporation moved forward with the USD 4.9 billion acquisition of Inari Medical in early 2025, expanding its medical technology offerings in the peripheral vascular disease space and aligning device innovation with its broader surgical and vascular portfolio.

✅ Sanofi agreed to acquire Blueprint Medicines for over USD 9 billion in June 2025, a strategic move to bolster its rare immunology and targeted therapy pipeline by adding approved drugs and advanced candidates that address complex immune-related conditions

Key Players:-
Novartis AG | GSK plc | Astellas Pharma Inc. | Merck & Co., Inc. | Johnson & Johnson Services, Inc. | Pfizer Inc. | Sanofi SA | Bayer AG | Zydus Lifesciences Limited | Wellona Pharma

Key Segments

By Disease Type:
The market includes benign prostatic hyperplasia (BPH), prostate cancer, prostatitis, and others. Prostate cancer holds a significant share due to rising incidence rates globally and growing awareness about early screening. Increasing aging male population and lifestyle-related risk factors are further driving demand for advanced diagnostic and therapeutic solutions across all disease categories.

By Diagnosis:
Diagnostic segmentation covers PSA testing, digital rectal examination (DRE), biopsy, imaging (MRI, CT, ultrasound), and other molecular tests. PSA testing remains widely adopted due to its cost-effectiveness and accessibility, while advanced imaging technologies are gaining traction for accurate detection and staging, improving early diagnosis and treatment planning.

By Treatment:
Treatment options include medications, minimally invasive therapies, surgery, radiation therapy, hormone therapy, and chemotherapy. Hormone therapy and targeted treatments are expanding rapidly due to technological advancements and increasing regulatory approvals. The growing preference for minimally invasive procedures is also contributing to market growth.

By End User:
Key end users include hospitals, specialty clinics, ambulatory surgical centers, and diagnostic laboratories. Hospitals dominate the segment owing to availability of advanced treatment infrastructure and multidisciplinary care, while specialty clinics are witnessing growth due to rising outpatient procedures and focused prostate care services.

Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=prostate-health-market?prtk

Market Drivers

• Rising Incidence of Prostate Disorders: Increasing prevalence of conditions like prostate cancer and benign prostatic hyperplasia (BPH) due to aging demographics and lifestyle factors is driving demand for diagnostic, therapeutic, and management solutions.

• Advancements in Diagnostics and Treatment Technologies: Innovations such as next-generation imaging ( multiparametric MRI), AI-enhanced diagnostics, biomarker testing, minimally invasive procedures, and precision medicine are improving early detection and clinical outcomes.

• Growing Awareness and Education on Prostate Health: Public health initiatives and education campaigns are increasing routine screening adoption and proactive patient engagement, leading to earlier diagnosis and expanded market uptake.

• Integration of Telehealth and Digital Health Solutions: Telemedicine and remote care platforms are facilitating easier access to prostate health consultations and follow-ups, especially for preventive care and chronic condition management.

• Expansion of Personalized and Preventive Care Models: Shift toward patient-centric care with personalized treatment regimens, home-based monitoring solutions, and preventive health approaches is boosting demand across diagnostic and therapeutic segments.

Regional Insights

North America: 45% - Largest share, driven by advanced healthcare infrastructure, high screening rates, strong R&D investment, and significant prevalence of prostate disorders.

Europe: 25% - Strong positioning supported by established healthcare systems, public health programs, and rising awareness among aging populations.

Asia Pacific: 21% - Fastest-growing region, fueled by expanding healthcare access, rising awareness, and increasing patient pool in China, India, Japan, and South Korea.

Latin America: 5% - Smaller share currently, with growth potential tied to increased healthcare initiatives and screening adoption.

Middle East & Africa: 5% - Emerging markets with improving healthcare access and prostate health awareness campaigns.

Speak to Our Analyst and Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/prostate-health-market?prtk

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.